PATENT CLAIM ANALYSIS

Application Number: 15883271
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["424", "464000"]

Abstract:
The invention relates to a monolithic pharmaceutical dosage form comprising a hot melt-extruded first segment (S 1 ) and a second segment (S 2 ); wherein the first segment (S 1 ) contains at least a first pharmacologically active ingredient (A 1 ) and/or the second segment (S 2 ) contains at least a second pharmacologically active ingredient (A 2 ); and the segment (S 1 ) and/or the segment (S 2 ) is tamper-resistant and/or exhibits a breaking strength of at least 300 N.

Claim (Index 12):
A monolithic pharmaceutical dosage form according to  claim 1 , wherein\n (a) the first segment (S 1 ) exhibits a breaking strength of at least 300 N and provides prolonged release of the first pharmacologically active ingredient (A 1 ) contained therein, whereby said first pharmacologically active ingredient (A 1 ) is an opioid; and\n (a1) the second segment (S 2 ) exhibits a lower breaking strength than the first segment (S 1 ) and provides prolonged release of the second pharmacologically active ingredient (A 2 ) contained therein, whereby said second pharmacologically active ingredient (A 2 ) is an NSAID; or \n (a2) the second segment (S 2 ) exhibits a lower breaking strength than the first segment (S 1 ) and provides immediate release of the second pharmacologically active ingredient (A 2 ) contained therein, whereby said second pharmacologically active ingredient (A 2 ) is an NSAID; or \n (a3) the second segment (S 2 ) exhibits a breaking strength of at least 300 N and provides prolonged release of the second pharmacologically active ingredient (A 2 ) contained therein, whereby said second pharmacologically active ingredient (A 2 ) is an NSAID; or \n (a4) the second segment (S 2 ) exhibits a breaking strength of at least 300 N and provides immediate release of the second pharmacologically active ingredient (A 2 ) contained therein, whereby said second pharmacologically active ingredient (A 2 ) is an NSAID; or \n (a5) the second segment (S 2 ) exhibits a breaking strength of at least 300 N and provides prolonged release of the second pharmacologically active ingredient (A 2 ) contained therein, whereby said second pharmacologically active ingredient (A 2 ) is identical to the first pharmacologically active ingredient (A 1 ); or \n (a6) the second segment (S 2 ) exhibits a breaking strength of at least 300 N and provides immediate release of the second pharmacologically active ingredient (A 2 ) contained therein, whereby said second pharmacologically active ingredient (A 2 ) is identical to the first pharmacologically active ingredient (A 1 ); or \n (a7) the second segment (S 2 ) exhibits a breaking strength of at least 300 N and provides prolonged release of the second pharmacologically active ingredient (A 2 ) contained therein, whereby said second pharmacologically active ingredient (A 2 ) is an opioid which is different from the first pharmacologically active ingredient (A 1 ); or \n (a8) the second segment (S 2 ) exhibits a breaking strength of at least 300 N and provides immediate release of the second pharmacologically active ingredient (A 2 ) contained therein, whereby said second pharmacologically active ingredient (A 2 ) is an opioid which is different from the first pharmacologically active ingredient (A 1 ); \n or (b) the second segment (S 2 ) exhibits a breaking strength of at least 300 N and provides prolonged release of the second pharmacologically active ingredient (A 2 ) contained therein, whereby said second pharmacologically active ingredient (A 2 ) is an opioid; and\n (b1) the first segment (S 1 ) exhibits a lower breaking strength than the second segment (S 2 ) and provides prolonged release of the first pharmacologically active ingredient (A 1 ) contained therein, whereby said first pharmacologically active ingredient (A 1 ) is an NSAID; or \n (b2) the first segment (S 1 ) exhibits a lower breaking strength than the second segment (S 2 ) and provides immediate release of the first pharmacologically active ingredient (A 1 ) contained therein, whereby said first pharmacologically active ingredient (A 1 ) is an NSAID; or \n (b3) the first segment (S 1 ) exhibits a breaking strength of at least 300 N and provides prolonged release of the first pharmacologically active ingredient (A 1 ) contained therein, whereby said first pharmacologically active ingredient (A 1 ) is an NSAID; or \n (b4) the first segment (S 1 ) exhibits a breaking strength of at least 300 N and provides immediate release of the first pharmacologically active ingredient (A 1 ) contained therein, whereby said first pharmacologically active ingredient (A 1 ) is an NSAID.

Metadata:
- Claim Count in Document: 24.0
- Percentile: 86.0
- Lexical Diversity: 2.34146
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14287348', '13864450', '14287512', '14327671', '14979888']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7454360500981736
- 35 USC 102 Novelty (BERT): 0.5251692206339464
- Combined Prediction Score: 0.7234093671517509
- Mean Citation Score: 313.37790000000007
- Max Citation Score: 341.29034
- Similarity Product: 250.6835695899332

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test